{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:08Z","timestamp":1788797828655,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T00:00:00Z","timestamp":1377734400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40268-013-0026-4","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T03:28:45Z","timestamp":1377660525000},"page":"207-213","source":"Crossref","is-referenced-by-count":4,"title":["Ranolazine Reduces Patient-Reported Angina Severity and Frequency and Improves Quality of Life in Selected Patients with Chronic Angina"],"prefix":"10.1007","volume":"13","author":[{"given":"Joseph B.","family":"Muhlestein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Grehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,29]]},"reference":[{"issue":"1","key":"26_CR1","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","volume":"127","author":"AS Go","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics\u20142013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6\u2013245.","journal-title":"Circulation"},{"issue":"2","key":"26_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heart.87.2.140","volume":"87","author":"B Brorsson","year":"2002","unstructured":"Brorsson B, Bernstein SJ, Brook RH, Werko L, for the SECOR\/SBU Project Group. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002;87(2):140\u20135.","journal-title":"Heart"},{"issue":"3","key":"26_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/JCN.0b013e31824af56e","volume":"28","author":"P Pragodpol","year":"2013","unstructured":"Pragodpol P, Ryan C. Critical review of factors predicting health-related quality of life in newly diagnosed coronary artery disease patients. J Cardiovasc Nurs. 2013;28(3):277\u201384.","journal-title":"J Cardiovasc Nurs"},{"issue":"11 Suppl.","key":"26_CR4","first-page":"S358","volume":"10","author":"HS Javitz","year":"2004","unstructured":"Javitz HS, Ward MM, Watson JB, Jaana M. Cost of illness of chronic angina. Am J Manag Care. 2004;10(11 Suppl.):S358\u201369.","journal-title":"Am J Manag Care"},{"issue":"16","key":"26_CR5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","volume":"169","author":"JF Beltrame","year":"2009","unstructured":"Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med. 2009;169(16):1491\u20139.","journal-title":"Arch Intern Med"},{"issue":"25","key":"26_CR6","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, et al. American College of Cardiology Foundation\/American Heart Association Task Force. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354\u2013471.","journal-title":"Circulation"},{"key":"26_CR7","first-page":"451","volume-title":"Essential cardiology: principles and practice","author":"SR Atmakuri","year":"2005","unstructured":"Atmakuri SR, Gollob MH, Kleiman NS. Stable Angina. In: Rosendorff C, editor. Essential cardiology: principles and practice. 2nd ed. Totowa: Humana Press; 2005. p. 451\u201370.","edition":"2"},{"key":"26_CR8","unstructured":"Ranexa [package insert]. Foster City, CA; Gilead Sciences, Inc.; 2011."},{"issue":"3","key":"26_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309\u201316.","journal-title":"JAMA"},{"issue":"5","key":"26_CR10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","volume":"4","author":"PK Mehta","year":"2011","unstructured":"Mehta PK, Goykhman P, Thomson LEJ, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514\u201322.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"26_CR11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.108.798009","volume":"1","author":"SV Arnold","year":"2008","unstructured":"Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008;1(2):107\u201315.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"26_CR12","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU Assessment Manual For Psychopharmacology, DHEW Publication No. ADM 76\u2013338. Washington, DC: US Government Printing Office; 1976.","DOI":"10.1037\/e591322011-001"},{"issue":"1","key":"26_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/01.CIR.0000020688.24874.90","volume":"106","author":"JA Spertus","year":"2002","unstructured":"Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106(1):43\u20139.","journal-title":"Circulation"},{"key":"26_CR14","doi-asserted-by":"crossref","unstructured":"Venkitachalam L, Kip KE, Mulukutla SR, et al. for the NHLBI-sponsored Dynamic Registry Investigators. Temporal trends in patient-reported angina at one year after percutaneous coronary revascularization in the stent era: a report from the NHLBI-sponsored 1997\u20132006 dynamic registry. Circ Cardiovasc Qual Outcomes. 2009;2(6):607\u201315.","DOI":"10.1161\/CIRCOUTCOMES.109.869131"},{"issue":"7","key":"26_CR15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa072771","volume":"359","author":"WS Weintraub","year":"2008","unstructured":"Weintraub WS, Spertus JA, Kolm P, for the COURAGE Trial Research Group, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677\u201387.","journal-title":"N Engl J Med"},{"issue":"15","key":"26_CR16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, for the COURAGE Trial Research Group, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"26_CR17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0735-1097(99)00637-3","volume":"35","author":"SJ Pocock","year":"2000","unstructured":"Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA, for the RITA-2 Trial Participants. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. J Am Coll Cardiol. 2000;35(4):907\u201314.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"26_CR18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1517\/14656566.2012.740458","volume":"13","author":"U Thadani","year":"2012","unstructured":"Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012;13(17):2555\u201363.","journal-title":"Expert Opin Pharmacother"},{"issue":"17","key":"26_CR19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1517\/14656566.2012.741592","volume":"13","author":"G Cocco","year":"2012","unstructured":"Cocco G. Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia? Expert Opin Pharmacother. 2012;13(17):2429\u201332.","journal-title":"Expert Opin Pharmacother"},{"key":"26_CR20","unstructured":"Cocco G. Indicated and off-label use of ranolazine. E J Cardiol Pract. 2013;11(18)."},{"key":"26_CR21","doi-asserted-by":"crossref","unstructured":"Phelps CE, Buysman EK, Gomez Rey G. Costs and clinical outcomes associated with use of ranolazine for treatment of angina. Clin Ther. 2012;34(6):1395\u2013407 e4.","DOI":"10.1016\/j.clinthera.2012.04.025"},{"issue":"1","key":"26_CR22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1345\/aph.1Q487","volume":"46","author":"DN Reeder","year":"2012","unstructured":"Reeder DN, Gillette MA, Franck AJ, Frohnapple DJ. Clinical experience with ranolazine in a veteran population with chronic stable angina. Ann Pharmacother. 2012;46(1):42\u201350.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"26_CR23","first-page":"131","volume":"20","author":"G Cocco","year":"1992","unstructured":"Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131\u20138.","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0026-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0026-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0026-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T02:50:51Z","timestamp":1563763851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0026-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,29]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0026-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718281390.793491147","asserted-by":"object"}]},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,29]]}}}